Today the company Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB is changing its name to AQILION AB. The name change marks a new phase in the development of the company, with a new strategy and identity. The decision was formally taken at an Extraordinary General Meeting in February, and the name is now registered. In conjunction with the name change, a new graphic profile is being developed that will reflect the new Aqilion strategy and identity.
Aqilion is a Swedish life science company that focuses on pharmaceutical projects with
potential to improve quality of life for patients, while generating value for health services
and society. Aqilion searches for opportunities – for ideas based on solid research resting
on a firm biological foundation, and offering both clinical relevance and patient benefit.
The company identifies unique pharmaceutical projects in the early phase of drug
discovery and develops them in preparation for clinical trials with the aim of attracting
industrial partners and buyers, who in turn have the capacity to continue clinical
development and take the product to market. Aqilion provides capital and an experienced
team that, along with specialists and innovators, tailors the project organization to each
The name Aqilion derives from Aquila, the Latin name of a genus that includes eagles. The
name of the company symbolizes an astute and versatile organization that can apply the
keen-sighted perspective of the eagle with great precision to find the early life science
projects that are a perfect fit for the Aqilion business model. Aquila is also the name of a
constellation that is visible in the northern hemisphere. The Nordic constellation reflects
the potential of close collaboration in networks.
“We have high ambitions and want to act both locally and globally. A strong and clear
brand is essential for our success. We also want to mark a new phase in the development
and strategy of the company with a name change. The name Aqilion feels right; it is
unique and its origin reflects who we are and who we want to be,” says Sarah Fredriksson,
CEO, AQILION AB.
More information can be found on the new website, www.www.aqilion.com, which is being launched today.
About AQILION AB
Aqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications (high-cost, high complexity and/or high touch drugs) and orphan drugs (drugs to treat diseases so rare that they would be unprofitable to produce without government assistance) are of particular interest.
Aqilion has its headquarters in Helsingborg, Sweden. Please visit www.www.aqilion.com.